

Mathijs C Bunck

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3766166/publications.pdf>

Version: 2024-02-01

21
papers

2,451
citations

471509

17
h-index

713466

21
g-index

21
all docs

21
docs citations

21
times ranked

3019
citing authors

#	ARTICLE	IF	CITATIONS
1	Exenatide improves β -cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial. <i>European Journal of Endocrinology</i> , 2016, 175, 345-352.	3.7	25
2	Effect of 3 Years of Treatment With Exenatide on Postprandial Glucagon Levels. <i>Diabetes Care</i> , 2016, 39, e42-e43.	8.6	9
3	Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients*. <i>Journal of Diabetes</i> , 2012, 4, 181-185.	1.8	53
4	Postprandial metabolic responses to mixed versus liquid meal tests in healthy men and men with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2011, 94, 449-455.	2.8	25
5	Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 374-377.	4.4	82
6	Effects of Exenatide on Measures of β -Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2011, 34, 2041-2047.	8.6	221
7	Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition. <i>Diabetes Care</i> , 2010, 33, 1734-1737.	8.6	139
8	Acute and 2-week exposure to prednisolone impair different aspects of β -cell function in healthy men. <i>European Journal of Endocrinology</i> , 2010, 162, 729-735.	3.7	147
9	One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress. <i>Atherosclerosis</i> , 2010, 212, 223-229.	0.8	118
10	One-Year Treatment With Exenatide Improves β -Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients. <i>Diabetes Care</i> , 2009, 32, 762-768.	8.6	354
11	Fifty-two-Week Treatment With Diet and Exercise Plus Transdermal Testosterone Reverses the Metabolic Syndrome and Improves Glycemic Control in Men With Newly Diagnosed Type 2 Diabetes and Subnormal Plasma Testosterone. <i>Journal of Andrology</i> , 2009, 30, 726-733.	2.0	282
12	Differential effects of cross-sex hormonal treatment on plasma asymmetric dimethylarginine (ADMA) in healthy male-to-female and female-to-male transsexuals. <i>Atherosclerosis</i> , 2009, 206, 245-250.	0.8	12
13	Autonomous prolactin secretion in two male-to-female transgender patients using conventional oestrogen dosages. <i>BMJ Case Reports</i> , 2009, 2009, bcr0220091589-bcr0220091589.	0.5	33
14	Long-Term Treatment of Transsexuals with Cross-Sex Hormones: Extensive Personal Experience. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 19-25.	3.6	268
15	Effects of Sex Steroids on the Neurotransmitter-Specific Aromatic Amino Acids Phenylalanine, Tyrosine, and Tryptophan in Transsexual Subjects. <i>Neuroendocrinology</i> , 2008, 88, 103-110.	2.5	18
16	Lack of association of liver fat with model parameters of β -cell function in men with impaired glucose tolerance and type 2 diabetes. <i>European Journal of Endocrinology</i> , 2008, 159, 251-257.	3.7	15
17	Pancreatic Fat Content and β -Cell Function in Men With and Without Type 2 Diabetes. <i>Diabetes Care</i> , 2007, 30, 2916-2921.	8.6	331
18	Incretin mimetics as a novel therapeutic option for hepatic steatosis. <i>Liver International</i> , 2006, 26, 1015-1017.	3.9	112

#	ARTICLE	IF	CITATIONS
19	Transsexuals and competitive sports. <i>European Journal of Endocrinology</i> , 2004, 151, 425-429.	3.7	68
20	Androgen Replacement Therapy. <i>Drugs</i> , 2004, 64, 1861-1891.	10.9	97
21	Transdermal testosterone delivery: testosterone patch and gel. <i>World Journal of Urology</i> , 2003, 21, 316-319.	2.2	42